Skip to search formSkip to main contentSkip to account menu

siltuximab

Known as: Anti-IL-6 Chimeric Monoclonal Antibody 
A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (2)

Antineoplastic AgentsMonoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen bindingsiltuximab 100 MG Injection [Sylvant]

Narrower (2)

cClB8 monoclonal antibodymonoclonal antibody CNTO 328

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
PENGARUH SENAM PERSADIA 1 TERHADAP KADAR IL-6 DAN KOLESTEROL TOTAL DARAH PADA IBU PKK LIDAH WETAN SURABAYA
PENDAHULUAN. Senam Persadia 1 merupakan pengembangan dari senam diabetes sebelumnya dengan prinsip aerobik, dan memperbanyak… 
2017
2017
Association between interleukin-6-174 G > C and-634 C > G polymorphism and diabetic nephropathy : a meta-analysis
Introduction: We aimed to meta-analyze the association of interleukin (IL)-6 -174G>C and -634C>G polymorphisms with Diabetic… 
2017
2017
Length Defective regulation of autoreactive IL-6-producing transitional B lymphocytes is associated with disease in patients with systemic sclerosis
Background: Systemic Sclerosis (SSc) has the highest case-specific mortality of any rheumatic disease and has no effective… 
2016
2016
Динамика провоспалительных цитокинов у детей, родившихся у женщин с осложненной беременностью, в зависимости от течения раннего периода адаптации
Objective: to estimate the time course of changes in proinflammatory cytokines during early neonatal adaptation in infants born… 
2016
2016
Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.
  • Prescrire international
  • 2016
  • Corpus ID: 25310913
Multicentric Castleman's disease is a rare lymphoproliferative disorder characterised by disseminated lymphadenopathy. Symptoms… 
2014
2014
Novartis' lung cancer ALK inhibitor approved
2014
2014
[The protective role of interleukin-6 monoclonal antibody on experimental autoimmune myocarditis and its mechanism].
OBJECTIVE To investigate the therapeutic effect of IL-6 mAb on experimental autoimmune myocarditis (EAM) in rats, and search the… 
2014
2014
FDA Approves Siltuximab for Castleman Disease
The FDA has approved siltuximab (Sylvant) for the treatment of multicentric Castleman disease, a disorder of the lymph nodes that… 
2013
2013
Siltuximab New Treatment Option for Multicentric Castleman Disease
Patients with the rare and potentially deadly multicentric Castleman disease were able to achieve durable tumor and symptomatic… 
2011
2011
Multiple roles of interleukin-6 in prostate cancer